Stockreport

ASH 2025: Cellectis Presents Development Plan to Further Enhance High Response Rate Observed for Eti-cel in r/r NHL

Cellectis S.A. - American Depositary Shares  (CLLS) 
Last cellectis s.a. - american depositary shares earnings: 3/4 04:30 pm Check Earnings Report
US:NASDAQ Investor Relations: cellectis.com/en/investors
PDF Eti-cel showed an 88% ORR and 63% CR (n=8) at current dose level in r/r NHL after =2 prior lines of therapyIn vivo data suggest IL-2 may further enhance response rates a [Read more]